Virological response and effect of viral clearance in patients with decompensated hepatitis C cirrhosis treated with Sofosbuvir plus daclatasvir with or without Ribavirin

Trial Profile

Virological response and effect of viral clearance in patients with decompensated hepatitis C cirrhosis treated with Sofosbuvir plus daclatasvir with or without Ribavirin

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C; Liver cirrhosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 New trial record
    • 05 Dec 2017 Primary endpoint (SVR12 at 12 weeks after completion of treatment) has been met, as per results published in the Alimentary Pharmacology and Therapeutics.
    • 05 Dec 2017 Results published in the Alimentary Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top